E2F reporter melanoma cells
A modified melanoma cell line capable of quantification of the effects of MEK inhibitors and CDK4/6 inhibitors in a quantitative, temporal and non-invasive manner both in vitro and in vivo.
1. A kit for testing and determining the efficacy of a compound of interest to inhibit E2 Factor (E2F) activity comprising:
a reporter cell line, wherein the reporter cell line comprises a 1205Lu melanoma cancer cell line transduced with
(1) a first lentiviral vector encoding an EGFP-Firefly luciferase fusion gene under the control of E2F transcriptional response elements, and
(2) a second lentiviral vector encoding tdTomato fluorescent protein.
2. A method of testing the efficacy of a compound of interest to inhibit E2F activity comprising applying the compound of interest to a reporter cell line, wherein the reporter cell line comprises a 1205Lu melanoma cancer cell line transduced with
(1) a first lentiviral vector encoding an EGFP-Firefly luciferase fusion gene under the control of E2F transcriptional response elements, and
(2) a second lentiviral vector encoding tdTomato fluorescent protein.
3. A method of testing the efficacy of a compound of interest to inhibit E2F activity comprising applying at least two compounds of interest to a reporter cell line, wherein the reporter cell line comprises a 1205Lu melanoma cancer cell line transduced with
(1) a first lentiviral vector encoding an EGFP-Firefly luciferase fusion gene under the control of E2F transcriptional response elements, and
(2) a second lentiviral vector encoding tdTomato fluorescent protein.
4. The method of claim 2 , further comprising incubating the reporter cell line after applying of the compound of interest.
5. The method of claim 4 , wherein the amount of firefly luciferase activity is compared to the amount of tdTomato activity in the reporter cell line.
6. The kit of claim 1 , wherein the reporter cell line is suitable for use in vitro or in vivo.